Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Zai Lab prepares to report second-quarter 2026 results as investors assess revenue recovery, new China product launches and progress across its oncology and neuroscience pipeline. Representative image.
Pharma & Biotech

Zai Lab’s August 6 earnings could reveal whether its 2026 commercial reset is starting to work

Zai Lab reports Q2 2026 results on August 6 as investors assess revenue pressure, COBENFY and TIVDAK launches, and zoci pipeline progress.

Read More
Clinical researchers review Phase 3 data for plozasiran after Arrowhead Pharmaceuticals reported substantial triglyceride reductions and fewer acute pancreatitis events in the SHASTA-3 and SHASTA-4 studies. Representative image.
Pharma & Biotech

SHASTA-3 and SHASTA-4 results support Arrowhead Pharmaceuticals’ planned plozasiran FDA filing

Arrowhead’s Phase 3 SHASTA data show deep triglyceride reductions and fewer pancreatitis events, supporting a planned 2026 U.S. filing.

Read More
CareDx prepares to report second-quarter 2026 results as investors assess transplant diagnostics growth, Medicare coverage clarity and the company’s expansion into oncology testing. Representative image.
Medical Devices & Diagnostics

CareDx shares have doubled in 2026. Will July 30 earnings support the surge?

CareDx reports Q2 results on July 30 as investors assess transplant testing growth, Medicare coverage clarity and the Naveris strategy.

Read More
Tikva Allocell’s $8 million Series A financing will support development of TAVST01, an engineered EBV-specific B7-H3 CAR-T therapy designed for potential use against solid tumors. Representative image.
Pharma & Biotech

Can Tikva Allocell’s $8m bet solve the persistence problem holding back off-the-shelf CAR-T?

Tikva Allocell raises $8 million to advance TAVST01 toward an IND, testing an EBV-specific CAR-T approach for B7-H3-positive solid tumors.

Read More
TopGum eye health gummy combines 10 mg lutein with 2 mg zeaxanthin
Pharma & Biotech

Can TopGum turn brain and eye health into the next major gummy growth category?

TopGum is targeting cognition and eye health with new gummies, but evidence, claim discipline and brand adoption will decide commercial impact.

Read More
Marquis MD plans to bring premium concierge medicine, personalised primary care, pediatrics and advanced diagnostic services to Boca Raton, Florida, through a membership-based healthcare model. Representative image.
Medical Devices & Diagnostics

What will Marquis MD’s Boca Raton concierge medicine membership include?

Marquis MD plans an August Boca Raton launch with premium primary care, pediatrics and advanced diagnostics. See what will test the model.

Read More
**Representative image:** Sterile bioprocessing and cryopreservation operations illustrate how Repligen Corporation’s $1.5 billion BioLife Solutions acquisition could expand its cell therapy manufacturing capabilities.
Features & Analysis

Why Repligen’s $1.5bn BioLife Solutions deal could reshape cell therapy manufacturing

Read how Repligen’s $1.5 billion BioLife deal could expand its cell therapy manufacturing reach, recurring revenue and global customer base.

Read More
American Heart Association AI report suggests Ultromics EchoGo could support earlier HFpEF detection by bringing artificial intelligence into routine echocardiography workflows. Representative image.
Medical Devices & Diagnostics

Could Ultromics EchoGo improve early detection of heart failure with preserved ejection fraction?

Ultromics’ EchoGo model suggests earlier HFpEF detection, but prospective evidence will decide whether hospitals realize the projected gains.

Read More
Mentari Therapeutics’ additional $200 million private placement could provide substantial funding for the MT-001 and MT-002 migraine prevention pipeline through key Phase 2a clinical readouts. Representative image.
Pharma & Biotech

Mentari just raised another $200m for migraine, but can its PACAP antibodies clear the clinical test?

Mentari adds $200 million to fund MT-001 and MT-002 through Phase 2a, extending its PACAP migraine runway into 2029 ahead of the InMed merger.

Read More
Curis reports expanded emavusertib clinical responses in relapsed or refractory primary central nervous system lymphoma, strengthening interest in the investigational combination treatment strategy. Representative image.
Pharma & Biotech

Curis expands emavusertib PCNSL response pool as TakeAim CLL enrolment accelerates

Curis reports updated emavusertib responses in PCNSL and faster CLL enrolment, while durability, safety and funding remain critical tests.

Read More